Keyphrases
CX3CR1
100%
Trastuzumab
100%
HER2-positive
100%
Chemokine CX3CL1
100%
Natural Killer Cells
83%
Overexpression
66%
Tumor Cells
50%
Prolonged Survival
33%
MDA-MB-453
33%
HT-29
33%
Antibody-dependent Cellular Cytotoxicity
33%
Trastuzumab Therapy
33%
HER2+
33%
Tumor Growth
16%
Syngeneic
16%
HER2 Expression
16%
Tumor Suppression
16%
Mouse Tumor Model
16%
Cell Toxicity
16%
Lymphocyte Infiltration
16%
Mode of Action
16%
Cell Depletion
16%
Immune Cells
16%
Survival Time
16%
Lymphocytes
16%
Predictive Biomarker
16%
Breast Cancer
16%
HER2 Overexpression
16%
Prognostic Marker
16%
Cytotoxicity in Vitro
16%
SKBR3
16%
Trastuzumab Resistance
16%
Efficacy in Vivo
16%
Pharmacologic Targets
16%
4T1 Breast Cancer
16%
Membrane Binding
16%
Lung Metastasis
16%
Medicine and Dentistry
In Vitro
100%
Malignant Neoplasm
100%
Fractalkine
100%
Trastuzumab
100%
Natural Killer Cell
50%
Tumor Cell
37%
Antibody Dependent Cellular Cytotoxicity
25%
Breast Cancer
25%
Immunocompetent Cell
12%
Lung Metastasis
12%
Tumor Progression
12%
Natural Killer Cell Mediated Cytotoxicity
12%
Lymphocytic Infiltration
12%
SKBR3
12%
Biological Marker
12%
Survival Time
12%
Neoplasm
12%
Adhesive Agent
12%
Lymphocyte
12%
Cancer
12%
Biochemistry, Genetics and Molecular Biology
Chemokine
100%
Trastuzumab
100%
CX3CL1
100%
Natural Killer Cell
50%
Antibody Dependent Cellular Cytotoxicity
25%
Syngenic
12%
Immunocompetent Cell
12%
Lymphocyte
12%
Survival Time
12%
Tumor Progression
12%
Natural Killer Cell Mediated Cytotoxicity
12%
Mouse Model
12%